Skip to main content
Lasa Supergenerics Limited logo

Lasa Supergenerics Limited — Investor Relations & Filings

Ticker · LASA ISIN · INE670X01014 LEI · 984500B9EA5EC3R2F726 BSE.NS Manufacturing
Open in API
Filings indexed 453 across all filing types
Latest filing 2025-12-29 Regulatory Filings
Country IN India
Listing BSE.NS LASA

About Lasa Supergenerics Limited

https://lasalabs.com/

Lasa Supergenerics Limited is a vertically integrated manufacturer specializing in Active Pharmaceutical Ingredients (APIs) for both veterinary and human health applications. The company focuses on the research, development, and production of high-quality chemical intermediates and APIs. Its core product portfolio includes a significant range of anthelmintics, such as Albendazole, Fenbendazole, and Ricobendazole, alongside other specialized therapeutic categories. Utilizing advanced manufacturing facilities and a dedicated research and development wing, the organization emphasizes cost-effective production processes and stringent quality control standards. Lasa Supergenerics Limited serves a global clientele, providing essential components for pharmaceutical formulations and animal health products through its expertise in complex chemical synthesis and large-scale manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges informing about the closure of the trading window for insiders due to upcoming unaudited financial results for the quarter ended December 31, 2025. It references insider trading regulations and trading restrictions but does not contain any financial data, report, or detailed analysis. The document is short (1655 characters) and serves as a notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance-related notices that do not fit other categories.
2025-12-29 English
Change in Company Secretary/Compliance Officer
Board/Management Information Classification · 100% confidence The document is an announcement addressed to stock exchanges (BSE and NSE) regarding the appointment of a new Company Secretary and Compliance Officer, who is also a Key Managerial Personnel. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provides details about the appointment, including the date and profile of the appointee. There is no financial data, report, or detailed management discussion. The content fits the category of announcing changes in senior management or board members.
2025-12-15 English
Cessation
Board/Management Information Classification · 100% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) regarding the resignation of a Whole-time Director of the company, Mr. Prathmesh Chalke. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 30, which pertains to disclosure of events or information including changes in directors. The document includes the resignation letter and details required under the regulation. There is no financial data, no report attached or referenced as being published, and the content is focused solely on management change. Therefore, this document fits the category of Board/Management Information (MANG). The document length is under 5,000 characters and is not an announcement of a report publication or certification, so it is not RPA or RNS. Hence, the classification is MANG with high confidence.
2025-12-11 English
Updates
Regulatory Filings Classification · 95% confidence The document is a disclosure of related party transactions pursuant to Regulation 23(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. It provides detailed information about transactions with directors and related parties, including remuneration and sitting fees. This type of disclosure is a regulatory requirement but is not a full financial report or audit report. It is a specific regulatory filing related to compliance and disclosure obligations under SEBI regulations. The document length is 4478 characters, which is relatively short and focused on disclosure rather than a full report. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance disclosure document that does not constitute an annual report, audit report, or other specific report types.
2025-11-14 English
Outcome of Board Meeting
Regulatory Filings
2025-11-14 English
Integrated Filing- Financial
Regulatory Filings
2025-11-14 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.